Jagsonpal Pharmaceuticals (BOM:507789) YoY EBITDA Growth : 113.08% (As of Mar. 2025)

View and export this data going back to 1991. Start your Free Trial

What is Jagsonpal Pharmaceuticals YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Jagsonpal Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Mar. 2025 was 113.08%.

Jagsonpal Pharmaceuticals's EBITDA per Share for the three months ended in Mar. 2025 was ₹1.66.

Jagsonpal Pharmaceuticals YoY EBITDA Growth Historical Data

The historical data trend for Jagsonpal Pharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jagsonpal Pharmaceuticals YoY EBITDA Growth Chart

Jagsonpal Pharmaceuticals Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

YoY EBITDA Growth

Get a 7-Day Free Trial

114.09

21.56

27.53

-11.83

140.16

Jagsonpal Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
YoY EBITDA Growth	Get a 7-Day Free Trial															-34.78	-24.98	64.56	580.56	113.08

Jagsonpal Pharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Jagsonpal Pharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Mar. 2025 is calculated as:

	YoY EBITDA Growth (A: Mar. 2025 )
=	(EBITDA per Share (A: Mar. 2025 )	-	EBITDA per Share (A: Mar. 2024 ))	/	\| EBITDA per Share (A: Mar. 2024 ) \|
=	(11.722	-	4.881)	/	\| 4.881 \|
=	140.16 %

Jagsonpal Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Mar. 2025 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2025 )
=	(EBITDA per Share (Q: Mar. 2025 )	-	EBITDA per Share (Q: Mar. 2024 ))	/	\| EBITDA per Share (Q: Mar. 2024 )) \|
=	(1.662	-	0.78)	/	\| 0.78 \|
=	113.08 %

Jagsonpal Pharmaceuticals YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Jagsonpal Pharmaceuticals's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Jagsonpal Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jagsonpal Pharmaceuticals Ltd (BOM:507789) » Definitions » YoY EBITDA Growth

Traded in Other Exchanges

JAGSNPHARM:India

Address

3rd Floor, Phase – IV, Udyog Vihar, Plot No. 412-415, Nimai Tower, Gurugram, HR, IND, 122015

Website

https://www.jagsonpal.com

Jagsonpal Pharmaceuticals Ltd is a pharmaceutical company. It develops and manufactures active pharmaceutical ingredients and formulations like Capsule and Tablet. The company operates in the Gynaecology, Orthopaedics, Dermatology and Paediatric segments. Its brands comprise Lycored, Maintane, Metadec, Metabol, Doxypal DR, and others.

Jagsonpal Pharmaceuticals Headlines

No Headlines